Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab and anakinra versus standard of care for hyperinflammation and respiratory distress in SARS-CoV-2 infection
2020-001167-93Phase 2Terminated
- Sponsor
- Sobi
- Start
- Jun 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Emapalumab arm, Anakinra arm and Standard of care arm (3 arms). Primary endpoint: Treatment success by Day 15. Started Jun 2020; status: terminated.
02
Drugs
emapalumabanakinra
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001167-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001167-93.